Dexcom Eyes US FDA Clearance For 15-Day CGM, But Insurance Coverage Remains Uncertain

Upgrade could boost Dexcom’s competitive positioning against Abbott’s Libre 3 Plus.

Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.

The new device is expected to enhance patient experience by extending wear time beyond its current 10-day G7 sensor.

More from Business

More from Policy & Regulation